Circumcision is a traditional and religious ceremony in Turkey as in other Muslim countries (more than one billion people) and also for Jewish people [1, 2] . It is well known that social and cultural integration of haemophilic boys into society is one of the most important cornerstones of modern haemophilia therapy. In Muslim societies,`circumcision is the ®rst step to be a man'. Hence, haemophilic boys and their parents may have an inferiority complex because the boys are unable to be circumcised.
Fibrin glue is a topical biological adhesive, the eect of which imitates the ®nal stages of coagulation. Fibrin glue from pooled plasma has been used in Europe for many years for ®xation of skin grafts. Usefulness of the sealant as a potent haemostatic agent in the control of bleeding is well documented in the ®elds of plastic surgery, cardiovascular surgery, neurosurgery, otorhinolaryngology and dental care in patients with either normal or abnormal haemostasis [3±5] . Local use of ®brin glue is a safe and cost-eective tool to treat patients with haemophilia especially for dental extractions and oral surgery [3, 6, 7] . It has also been shown to be useful in circumcision of haemophilic boys [8] .
In this report, we evaluated the ecacy and reduction in costs of factor concentrates in circumcision by using ®brin glue in four children.
Case history
Four children with haemophilia (three A, one B) (factor level 5 2%) underwent circumcision using ®brin glue and factor substitution. All children were Caucasian, Turkish citizens and Muslims. Their ages were 8, 9, 12 and 17 years. No patient had inhibitors before intervention. Commercial heat-treated ®brin glue (Tisseel-Kit, Immuno AG, Vienna, Austria) was used for all patients.
Circumcision was carried out under general anaesthesia. The prepuce was cut o circumferentially and excised using the Gomco clamp technique. Major bleeding vessels on the shaft were fulgurated or tied. Then 1 mL of a twocomponent ®brin glue, prepared using thrombin 500 by the water bath method, was applied onto the denuded area through a 22-gauge needle. The skin edges were then approximated with 4/0 interrupted catgut sutures and the incision was covered again with the glue. The wound was covered with a gauze dressing and dampened with tranexamic acid three times a day. The dressing was removed 3 days after the operation.
All of the patients received oral tranexamic acid (50 mg kg 71 day 71 ; three times daily) for 7 days to delay the clot degradation. For patients with haemophilia A, intermediate-purity concentrates (Nordiate, Novo Nordisk, Denmark; Koate-HP, Bayer, USA; and Factor 8 Y, BPL, UK) were used. In haemophilia B, high-purity factor IX concentrate (Replenine, BPL, UK) was used. A bolus dose of concentrate was injected preoperatively to achieve an factor level activity in plasma of at least 50%. At the end of surgery, the factor level was checked and bolus injections were repeated. The replacement therapy was aimed to maintain a factor level of above 50% during the ®rst 4 days postoperatively.
Three other children with severe haemophilia A given only factor substitution without ®brin glue served as a control group. Their ages were 8, 9 and 14 years. They had no inhibitor.
Intermediate-factor concentrates, Koate-HP and Nordiate, were used in these patients together with tranexamic acid for 7 days. We used 8 days of factor substitution after the operation day to achieve and maintain a factor activity level of at least 50% in plasma.
All the children had an uncomplicated course after circumcision. Nobody had a decreased Hb level or required blood transfusion. Wound healing was normal and there was no wound infection or bleeding. Total costs were signi®cantly reduced to $6300 per patient when using ®brin glue plus 4 days of factor replacement compared with $13 702 per patient in the control group (P 5 0.01). A haemophilia B patient on high-purity and expensive factor IX concentrate was excluded from cost comparison.
Discussion
Fibrin glue is a solution of concentrated human ®brinogen which is activated by the addition of bovin thrombin and calcium chloride. The resultant clot aids local haemostasis and tissue sealing and is completely absorbed during wound healing without foreign body reaction or extensive ®brosis [3±5]. Fibrin glue is available in Europe and Canada as a haemostatic agent. A licence has not yet been given in the USA [3] . It is recently reported that the risk of viral transmission can be further reduced by using plasma from a single donor (home-made ®brin glue) [6±8] or using current viral inactivity procedures such as the solvent/detergent method [9] . Apart from the viral transmision risk, inhibitor formation is reported after using ®brin glue. Bovine thrombin preparations also contain bovine factor V. Antibodies against factor V or thrombin have been detected and shown to have crossreactivity with human factor V. The resulting de®ciency of factor V can produce a bleeding diathesis [10] . To day, all commercial products undergo one or more virus inactivation procedures, and all include ®brinogen, factor XIII and thrombin of human origin [3] . We follow up our patients periodically with respect to viral transmission and inhibitor formation.
Formerly, we were not able to use the ®brin glue in circumcision, owing to unavailablity in Turkey. Our cost of circumcision has recently been signi®cantly reduced after introduction of this method. It was common for haemophilia patients to be overtreated, because of a fear that they would develop excessive bleeding. Before using ®brin glue, our factor substitution duration was at least 7± 8 days, as with any other major procedures. Now, we use only 4 days of factor subtitution with ®brin glue. However, Martinowitz has suggested that ®brin glue, meticulous suturing and tranexamic acid are enough to cover the patient with factor concentrate for 2±3 days only (personal communication). We also plan to decrease the substitution duration in future as suggested by Martinowitz. Fibrin glue gave us the opportunity to reduce our treatment, and hence it reduces the cost, perhaps through a`placebo eect'. Morever, Martinowitz et al. reported that satisfactory local haemostasis with ®brin glue was obtained in some haemophilic patients without factor replacement for circumcision [8] . Even with 4 days of factor replacement, we can save half the cost of circumcision without any bleeding complication. We also plan to use continuous infusion of factor substitution for another means of cost saving.
Although our patient numbers are small, the message is clear. Our experience suggests that ®brin glue signi®cantly reduces the requirement of factor replacement. We believe that circumcision can be performed safely and at reduced cost using ®brin glue at the site of the surgical wound rather than small amounts of factor concentrates. We recommend that ®brin glue should be use in haemophilic boys for circumcision. 
